MSH|^~\&|LAB|RCH|||202003191311||ORU^R01|4188209|D|2.3|||AL|NE
PID|1||RC00007909|RC7657|LABTEST^GOING^TOTEST||19440615|F||||||||||RC000696/19|9874962522
OBR|1|40736^LAB|00030713^1903:C00010R^LAB^190320:C10^40736|522.2490^BHCG^Beta-HCG^^^21198-7||202003191309|202003191308|||||||202003191308||||||||||LAB|F||||
NTE|1||UCI SCENARIO 4D
OBX|1|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|5^^Y|IU/L|<10|N||A^S|F|||202003191311
NTE|1||Reference Intervals, (guideline only) FOR B-HCG (U/L):
NTE|2||
NTE|3||Male or non-pregnant female            Less than 10
NTE|4||Pregnant female:
NTE|5||Time after LMP:        Expected beta-HCG range(WHO 3rd IRP):
NTE|6||4th  week                               25 - 426
NTE|7||5th  week                               25 - 7340
NTE|8||6th  week                             1080 - 56500
NTE|9||10th week                            54100 - 288000
NTE|10||18th week                             8910 - 66000
NTE|11||31st week                             5310 - 27400
NTE|12||*************************NOTE*******************************
NTE|13||Occasional patients with heterophile antibodies may have
NTE|14||erroneous BHCG results. Serum BHCG should not be used for
NTE|15||routine pregnancy tests. Urine does not contain heterophile
NTE|16||antibodies and may be used where apparent discrepant results
NTE|17||are experienced.
NTE|18||Method:Roche COBAS